Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AVBP |
---|---|---|
09:32 ET | 348 | 27.56 |
09:35 ET | 200 | 27.345 |
09:37 ET | 100 | 27.345 |
09:46 ET | 100 | 27.18 |
09:48 ET | 1206 | 27.18 |
09:50 ET | 930 | 27.325 |
09:53 ET | 100 | 27.43 |
09:55 ET | 600 | 27.325 |
10:00 ET | 100 | 27.46 |
10:04 ET | 400 | 27.31 |
10:09 ET | 400 | 27.4 |
10:13 ET | 100 | 27.39 |
10:15 ET | 100 | 27.44 |
10:20 ET | 203 | 27.355 |
10:22 ET | 22855 | 27.375 |
10:24 ET | 32639 | 27.17 |
10:31 ET | 550 | 27 |
10:33 ET | 100 | 27.03 |
10:49 ET | 200 | 27.07 |
10:51 ET | 300 | 27.08 |
11:00 ET | 1000 | 27.27 |
11:02 ET | 200 | 27.46 |
11:05 ET | 100 | 27.53 |
11:16 ET | 359 | 27.41 |
11:18 ET | 500 | 27.55 |
11:27 ET | 1700 | 27.595 |
11:34 ET | 200 | 27.765 |
11:36 ET | 100 | 27.77 |
11:39 ET | 250 | 27.43 |
11:45 ET | 100 | 27.615 |
11:48 ET | 500 | 27.645 |
11:52 ET | 500 | 27.65 |
11:54 ET | 200 | 27.645 |
11:57 ET | 400 | 27.645 |
11:59 ET | 100 | 27.645 |
12:01 ET | 200 | 27.645 |
12:03 ET | 300 | 27.64 |
12:06 ET | 100 | 27.55 |
12:08 ET | 200 | 27.54 |
12:10 ET | 600 | 27.53 |
12:12 ET | 500 | 27.53 |
12:14 ET | 500 | 27.51 |
12:15 ET | 100 | 27.5 |
12:17 ET | 300 | 27.48 |
12:19 ET | 549 | 27.51 |
12:21 ET | 151 | 27.5 |
12:24 ET | 100 | 27.45 |
12:26 ET | 212 | 27.5 |
12:32 ET | 2021 | 27.515 |
12:33 ET | 100 | 27.525 |
12:39 ET | 200 | 27.525 |
12:46 ET | 1125 | 27.56 |
12:48 ET | 1557 | 27.55 |
12:50 ET | 100 | 27.63 |
01:00 ET | 1100 | 27.45 |
01:02 ET | 100 | 27.505 |
01:04 ET | 100 | 27.465 |
01:22 ET | 245 | 27.58 |
01:24 ET | 400 | 27.585 |
01:27 ET | 100 | 27.64 |
01:33 ET | 219 | 27.645 |
01:36 ET | 126 | 27.61 |
01:44 ET | 400 | 27.52 |
01:45 ET | 9194 | 27.435 |
01:51 ET | 300 | 27.28 |
01:54 ET | 700 | 27.36 |
02:07 ET | 1300 | 27.295 |
02:09 ET | 100 | 27.25 |
02:12 ET | 503 | 27.21 |
02:14 ET | 260 | 27.21 |
02:30 ET | 200 | 27.255 |
02:34 ET | 200 | 27.255 |
02:38 ET | 500 | 27.33 |
02:39 ET | 1594 | 27.07 |
02:43 ET | 600 | 27.06 |
02:54 ET | 100 | 27.0136 |
02:59 ET | 900 | 26.84 |
03:03 ET | 100 | 26.775 |
03:06 ET | 327 | 26.775 |
03:14 ET | 100 | 26.92 |
03:17 ET | 532 | 26.75 |
03:19 ET | 3075 | 26.58 |
03:26 ET | 350 | 26.66 |
03:28 ET | 222 | 26.73 |
03:35 ET | 404 | 26.84 |
03:37 ET | 200 | 26.875 |
03:39 ET | 100 | 26.875 |
03:42 ET | 1004 | 26.755 |
03:46 ET | 100 | 26.795 |
03:48 ET | 700 | 26.77 |
03:50 ET | 200 | 26.845 |
03:51 ET | 1108 | 26.82 |
03:53 ET | 438 | 26.853 |
03:55 ET | 435 | 26.84 |
03:57 ET | 2070 | 26.72 |
04:00 ET | 21418 | 26.59 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Arrivent Biopharma Inc | 893.0M | -10.1x | --- |
Nuvation Bio Inc | 908.7M | -1.2x | --- |
Septerna Inc | 915.2M | -87,160.0x | --- |
Bicara Therapeutics Inc | 870.1M | 0.0x | --- |
LENZ Therapeutics Inc | 943.8M | -4.8x | --- |
Rapport Therapeutics Inc | 823.7M | 0.0x | --- |
ArriVent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. It is also focused on development and commercialization of the ARR-002 program.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $893.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 33.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.62 |
Book Value | $4.73 |
P/E Ratio | -10.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.